<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AD581B04-691C-433C-8C67-A3A5A913FF0F"><gtr:id>AD581B04-691C-433C-8C67-A3A5A913FF0F</gtr:id><gtr:firstName>Kerry</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/63C3E142-9699-4954-9C25-42017C1FA8B3"><gtr:id>63C3E142-9699-4954-9C25-42017C1FA8B3</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Stevenson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A92977E-E8DA-4816-8D30-9175EA0FA66D"><gtr:id>4A92977E-E8DA-4816-8D30-9175EA0FA66D</gtr:id><gtr:firstName>Leonard</gtr:firstName><gtr:surname>Seymour</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700166"><gtr:id>1CD22735-C40C-4F00-8B69-3BC0C80D63DD</gtr:id><gtr:title>Development of a Generic Pharmacodynamic Reporter Model for Assessing in vivo Activity and Selectivity of Targeted siRNA</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700166</gtr:grantReference><gtr:abstractText>Short interfering RNAs (siRNAs) can reduce the expression of disease-related genes by binding to and mediating the degradation of mRNA (the intermediate of DNA and protein) to which they are complementary. However therapeutic siRNA must be delivered to appropriate parts of the body which is a significant challenge. If the organs are not directly accessible i.e. skin, eyes, muscles, then siRNA must be delivered via the blood stream. Currently there are no methods to sensitively determine both the quantity and efficacy of siRNA reaching the desired organ in a living animal. We propose to create a mouse that will express light (detected by a camera) in organs where siRNA has been delivered. Mouse models will be created by introducing two pieces of foreign DNA into every cell in the mouse, one that makes light emitting protein and one that makes a repressor protein that regulates light expression. When siRNA that specifically recognises the repressor mRNA enters cells the amount of repressor protein will fall and light will be generated. By combining target specificity and biological functionality this model will permit testing of various siRNA delivery mechanisms leading to improved design and effectiveness.</gtr:abstractText><gtr:technicalSummary>The major obstacle for development of short interfering RNA (siRNA) as a therapeutic agent is effective and selective delivery to the target site. Currently there are no models that jointly assess pharmacokinetic profiles and biological activity in living animals making it impossible to assess target selectivity and identify spatially off target effects. The ideal tool to facilitate development of delivery strategies would be a non-invasive in vivo model capable of giving time-resolved pharmacodynamic readout following siRNA administration. We propose to develop a transgenic mouse model carrying the lac operator-repressor system controlling luciferase expression in every tissue. Successful delivery of siRNA targeting lac repressor mRNA will down regulate lacI expression leading to derepression of the luciferase reporter gene and a positive readout detectable by CCD camera in real time. An easily detectable signal showing activity of siRNA in target and non-target tissues, will enable assessment of selectivity and potential toxicity of any siRNA targeting strategy. To achieve this aim we will generate founder lines expressing either lac I repressor protein or luciferase, downstream of lac operator elements, which will be crossed to generate progeny with a functional lac operon-repressor system. Using this model it will be possible to test novel and existing formulations of siRNA vectors for tissue targeted delivery.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>310260</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Media Centre Interviews Len Seymour</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ACDF10FF-B9BA-4EEE-84B6-BFE9B651DBC6</gtr:id><gtr:impact>Various, I have given many interviews on various topics and sometimes there is considerable feedback

Contacts from patients are always difficult, as they are hoping for medical benefit form experimental agents, and a key skill in this work is to pitch it to be encouraging without giving false hope</gtr:impact><gtr:outcomeId>54637970a2c4b0.97637782</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2009,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Journeys in the Genetic Jungle' Public Engagement Days Len Seymour</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AED1CB3C-B10C-49D5-9365-530E4663841B</gtr:id><gtr:impact>BSGT Public Awareness Day 'Journeys in the Genetic Jungle: progress in gene and cell therapy'. Talks, presentations and Q&amp;amp;A sessions.

These events were targeted at teenagers and gave the public an opportunity to discuss and debate gene and cell therapy research with scientists, patients, journalists and clinicians, and to think about the impact that this research has on themselves and society. The events were very well attended (with over 200 visitors per day) and generated extremely positive feedback from the public.</gtr:impact><gtr:outcomeId>CA442111FAD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxfordshire Science Festival Len Seymour</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DB5BBBFA-08D8-47D4-BBF1-F97F5DC29DDF</gtr:id><gtr:impact>Good questions form the schools who attended

Requests for slides</gtr:impact><gtr:outcomeId>546378a9c08a45.17027758</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Engagement Day: European Society for Gene &amp; Cell Therapy Len Seymour</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EA8A94E-B3C5-4C5A-9326-38939A2142B4</gtr:id><gtr:impact>Sharing scientific ideas and goals with patient groups and their families promotes discussion of the ethics and potential risks and benefits, and informs better understanding both for the scientists and for the members of the public

Good feedback from lay members including requests for my slides</gtr:impact><gtr:outcomeId>54637855189960.02922468</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Polymers for efficient coating of biological surfaces</gtr:description><gtr:grantRef>G0700166</gtr:grantRef><gtr:id>C5B2A211-A7FF-46E5-B9D3-69B3084FA719</gtr:id><gtr:impact>Polymers for efficient coating of biological surfaces</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7f338be37e9.45222050</gtr:outcomeId><gtr:patentId>KR20110097938 (A)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Polymers for efficient coating of biological surfaces</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a novel assay to quantify siRNA (or miRNA) using a PCR-based approach. Briefly primers were designed that would compete with an siRNA of interest. The siRNA was then quantified such that it would compete with the primer to bind a template DNA employed in a qPCR reaction. We confirmed that the technique could be used to quantify siRNA in relevant biological samples such as cell lysate in order to quantify siRNA pharmacokinetics.</gtr:description><gtr:id>5C724EB5-23BC-498E-A074-AEDD7EA46AD0</gtr:id><gtr:impact>Published PMID 19004870</gtr:impact><gtr:outcomeId>224743DB7F9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Competitive quantitative PCR</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19004870</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated several transgenic mouse lines expressing luciferase under the control of the Huntington's Disease Promoter in which are embedded lac operator elements. This line expresses luciferase ubiquitously throughout the mouse. We have also generated transgenic mouse lines that express the lac repressor protein under the control of the human beta actin promoter that expresses throughout the mouse. We are in the process of breeding these lines (reporter and repressor) to create a working positive reporter line that will express luciferase when the repressor is disabled by either systemic IPTG of siRNA administration.</gtr:description><gtr:id>CB086E44-EFAF-4E4D-9505-8E76DA4E7EA0</gtr:id><gtr:impact>When comploted we will publish these results and make the model available to other researchers</gtr:impact><gtr:outcomeId>815B1C1FD60</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic Mouse lines for Positive Reporter Mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C6B3F86-B728-4E49-B516-FD230FE7F4DB</gtr:id><gtr:title>Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3594678c3a41c433fe8c85e17e9a79bf"><gtr:id>3594678c3a41c433fe8c85e17e9a79bf</gtr:id><gtr:otherNames>Stevenson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>KzQitVPd11T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7485668-F6A5-4AA1-9BB0-7794E9057855</gtr:id><gtr:title>Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1dc3167cc0ada7968e4830768b41f7e"><gtr:id>a1dc3167cc0ada7968e4830768b41f7e</gtr:id><gtr:otherNames>Bachtarzi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>545220ea5818e0.10476272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>204F4086-4742-4FD3-9983-58CF4435857A</gtr:id><gtr:title>Quantitative characterization of cell transduction by HSV-1 amplicons using flow cytometry and real-time PCR.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dc896818f1455aaddced3f01c07a7de"><gtr:id>4dc896818f1455aaddced3f01c07a7de</gtr:id><gtr:otherNames>El-Sherbini YM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>5461d629715692.75770632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90E5F0CA-E70A-47FC-86CC-5529578E54EE</gtr:id><gtr:title>Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07c46cf66185aa4171cceaaad9277612"><gtr:id>07c46cf66185aa4171cceaaad9277612</gtr:id><gtr:otherNames>Carlisle RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>5461d627db37a7.33795293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A8FE0ED-D75D-423B-A307-C58952D33C3F</gtr:id><gtr:title>Quantification of siRNA using competitive qPCR.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7aff762c9267a1de7cb751055848431e"><gtr:id>7aff762c9267a1de7cb751055848431e</gtr:id><gtr:otherNames>Liu WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>4DA2D4FE23F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>106EB71E-9527-4C78-87C4-840553CBFE24</gtr:id><gtr:title>Combination dual responsive polypeptide vectors for enhanced gene delivery.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb7081fed603e24ae27bc5050e7432f"><gtr:id>5bb7081fed603e24ae27bc5050e7432f</gtr:id><gtr:otherNames>Nasanit R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>5461d6285d4df9.44145844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A5114DF-98F8-435B-8DD0-BF83014BE7FC</gtr:id><gtr:title>Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.</gtr:title><gtr:parentPublicationTitle>Cancer gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3594678c3a41c433fe8c85e17e9a79bf"><gtr:id>3594678c3a41c433fe8c85e17e9a79bf</gtr:id><gtr:otherNames>Stevenson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0929-1903</gtr:issn><gtr:outcomeId>545b9ac0246513.04453464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF59594D-7B7F-4EC2-91D4-241CA9638F50</gtr:id><gtr:title>Establishment of a positive-readout reporter system for siRNAs.</gtr:title><gtr:parentPublicationTitle>Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7aff762c9267a1de7cb751055848431e"><gtr:id>7aff762c9267a1de7cb751055848431e</gtr:id><gtr:otherNames>Liu WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1747-0854</gtr:issn><gtr:outcomeId>5461d629982736.45470113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB527CBE-659F-47E6-A339-40BF116A0D73</gtr:id><gtr:title>Delivery of siRNA mediated by histidine-containing reducible polycations.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3594678c3a41c433fe8c85e17e9a79bf"><gtr:id>3594678c3a41c433fe8c85e17e9a79bf</gtr:id><gtr:otherNames>Stevenson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>5461d8d9045d11.84323341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>650979A4-C461-49B1-BA0E-3A09AFA9E239</gtr:id><gtr:title>Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability.</gtr:title><gtr:parentPublicationTitle>Human gene therapy methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c920a48c010fcd197a8e53ac335d183"><gtr:id>8c920a48c010fcd197a8e53ac335d183</gtr:id><gtr:otherNames>Kueberuwa G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6536</gtr:issn><gtr:outcomeId>5461d62a41be36.01925265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC2DDD6C-4ED0-458D-B844-17794FE73BB4</gtr:id><gtr:title>Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/914a5d9d73e66a78a254c31b21274506"><gtr:id>914a5d9d73e66a78a254c31b21274506</gtr:id><gtr:otherNames>Graham SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>545217f935bc44.29850103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64152F63-6D5C-480D-B8EF-235A1934EDE8</gtr:id><gtr:title>DYNAMICS OF POLYDISPERSE IRREVERSIBLE ADSORPTION: A PHARMACOLOGICAL EXAMPLE</gtr:title><gtr:parentPublicationTitle>Mathematical Models and Methods in Applied Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/489647d75858276396a29550115d4662"><gtr:id>489647d75858276396a29550115d4662</gtr:id><gtr:otherNames>ERBAN R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>58b8153fda4955.88439998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>738C076F-7843-47BC-80DE-D9CBE6909AEE</gtr:id><gtr:title>E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-a-activated human umbilical vein endothelial cells.</gtr:title><gtr:parentPublicationTitle>Journal of drug targeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1dc3167cc0ada7968e4830768b41f7e"><gtr:id>a1dc3167cc0ada7968e4830768b41f7e</gtr:id><gtr:otherNames>Bachtarzi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1026-7158</gtr:issn><gtr:outcomeId>54522144171e73.07456579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20015306-5514-4911-BBD1-3A0B7E2788D6</gtr:id><gtr:title>Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7aff762c9267a1de7cb751055848431e"><gtr:id>7aff762c9267a1de7cb751055848431e</gtr:id><gtr:otherNames>Liu WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0929-1903</gtr:issn><gtr:outcomeId>pm_53cd4c4d4c43c93f0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700166</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>